## CLAIMS

1. A compound of formula (Ia)




(Ia)

in which,

R1a is a hydrogen atom, a halogen atom, a nitrile group, a nitro group (NO2), a (C1-C6)alkyl group, a (C1-C6)alkyloxy group, a (C1-C6)alkylthio group, a -$NH_2$ group, a (C1-C6)alkylamino group, a (C1-C6)dialkylamino group, or a heterocyclic group;

R1b is a hydrogen atom, a (C1-C6)alkyloxy group, a (C1-C6)alkyl group or a heterocyclic group;

R1c is a hydrogen atom, a halogen atom, a (C1-C6)alkyl group, a (C1-C6)alkyloxy group, a (C1-C6)alkylthio group, a heterocyclic group, a cyano group, an amido group or a hydroxyl group;

R1d and R1e are, independently, a hydrogen atom, a halogen atom, a (C1-C6)alkyloxy group or a (C1-C6)alkyl group;

wherein at least one R1a, R1b, R1c, R1d, and R1e is not a hydrogen atom;

R2 is a (C1-C6)alkyl group, a (C2-C6)alkenyl group, a (C2-C6)alkynyl group, a (C3-C14)cycloalkyl group, a (C6-C14)aryl group optionally substituted by a ($C_1$-$C_6$)alkyl or a heterocyclic group optionally substituted by a (C1-C6)alkyl group,

R'2 is a hydrogen atom; a (C1-C6)alkyl group; a (C2-C6)alkenyl group; a (C2-C6)alkynyl group; a (C3-C14)cycloalkyl group; a (C6-C14)aryl group optionally substituted by a ($C_1$-$C_6$)alkyl group or by a halogen atom; or a heterocyclic group optionally substituted by a (C1-C6)alkyl group or by a halogen atom,

or R2 and R'2 can form, together with the carbon atom to which they are attached, a (C3-C14)cycloalkyl group or a heterocycloalkyl group;

L is a NR7-CO-CH2, NR7-CO-C(CH3)2, CO-NH-CH2, or CO-NH-C(CH3)2 group, a NR7-CO-(C1-C6)alkyl group, a NR7-CO-(C3-C14)cycloalkylgroup, or a NR7-CO-CR5R'5 group;

R5 and R'5 are independently, a hydrogen atom, or a (C1-C6)alkylgroup;

or R5 and R'5 can form, together with the carbon atom to which they are attached, a cycloalkyl group;

X1 and X2 are independently a CH group or a nitrogen atom;

R3 is a hydrogen atom, a (C1-C6)alkyl group, a carbonyl(C1-C6)alkyl group, a SO2R' group, a COOR' group, an amido group, a (C1-C6)alkylamido group, or a (C1-C6)dialkylamido group;

R' is a (C1-C6)alkyl group;

R4 is a hydrogen atom, a (C1-C6)alkyl group, or a halogen atom;

R7 is an hydrogen atom or a (C1-C6)alkyl group.

2. The compound according to claim 1, wherein:

R1a is a hydrogen atom, a halogen atom, a nitrile group, a nitro group (NO2), a (C1-C6)alkyl group, a (C1-C6)alkyloxy group, a (C1-C6)alkylthio group, a $-NH_2$ group, a (C1-C6)alkylamino group, a (C1-C6)dialkylamino group, or a heterocyclic group;

R1b is a hydrogen atom, a (C1-C6)alkyloxy group, a (C1-C6)alkyl group or a heterocyclic group;

R1c is a hydrogen atom, a halogen atom, a (C1-C6)alkyl group, a (C1-C6)alkyloxy group, a (C1-C6)alkylthio group, a heterocyclic group, a cyano group, an amido group or a hydroxyl group;

R1d and R1e are, independently, a hydrogen atom, a halogen atom, a (C1-C6)alkyloxy group or a (C1-C6)alkyl group;

wherein at least one R1a, R1b, R1c, R1d, and R1e is not a hydrogen atom;

R2 is a (C1-C6)alkyl group, a (C2-C6)alkenyl group, a (C2-C6)alkynyl group, a (C3-C14)cycloalkyl group, a (C6-C14)aryl group optionally substituted by a $(C_1-C_6)$alkyl or a heterocyclic group optionally substituted by a (C1-C6)alkyl group,

R'2 is a hydrogen atom; a (C1-C6)alkyl group; a (C2-C6)alkenyl group; a (C2-C6)alkynyl group; a (C3-C14)cycloalkyl group; a (C6-C14)aryl group optionally substituted by a $(C_1-C_6)$alkyl group or by a halogen atom; or a heterocyclic group optionally substituted by a (C1-C6)alkyl group or by a halogen atom,

or R2 and R'2 can form, together with the carbon atom to which they are attached, a (C3-C14)cycloalkyl group or a heterocycloalkyl group;

L is a NR7-CO-CH2, NR7-CO-C(CH3)2, CO-NH-CH2, or CO-NH-C(CH3)2 group
X1 and X2 are independently a CH group or a nitrogen atom;
R3 is a hydrogen atom, a (C1-C6)alkyl group, a carbonyl(C1-C6)alkyl group, a SO2R' group, a COOR' group, an amido group, a (C1-C6)alkylamido group, or a (C1-C6)dialkylamido group;
R' is a (C1-C6)alkyl group;
R4 is a hydrogen atom, a (C1-C6)alkyl group, or a halogen atom;
R7 is an hydrogen atom or a (C1-C6)alkyl group.

3. The compound according to claims 1 or 2, wherein:
R1a is a hydrogen atom, a halogen atom, a nitrile group, a nitro group (NO2), a (C1-C6)alkyl group, a (C1-C6)alkyloxy group, a (C1-C6)alkylthio group, a $-NH_2$ amino group, a (C1-C6)alkylamino group, a (C1-C6)dialkylamino group, a piperidinyl group, a pyrrolidinyl group, or an azepanyl group, wherein said piperidinyl, pyrrolidinyl or azepanyl group can be optionally substituted by at least one (C1-C6)alkyl group;
R1b is a hydrogen atom;
R1c is a hydrogen atom, a (C1-C6)alkyl group, or a (C1-C6)alkyloxy group; and
R2 is a (C1-C6)alkyl group, a (C3-C14)cycloalkyl group, a (C6-C14)aryl group, or a heteroaryl group, and R'2 is a hydrogen atom.

4. The compound according to any one of claims 1 to 3wherein X1 and X2 are nitrogen atoms or wherein X1 is a nitrogen atom and X2 is a CH group.

5. The compound according to any one of claims 1 to 4, wherein L is a NR7-CO-CH2, NR7-CO-C(CH3)2, CO-NH-CH2, or CO-NH-C(CH3)2 group.

6. The compound according to any one of claims 1 to 5, wherein R1b is a hydrogen atom.

7. The compound according to any one of claims 1 to 6, wherein R1d and R1e are hydrogen atoms.

8. The compound according to any one of claims 1 or 7, wherein
R1a is a heterocyclic group,
R1c is a hydrogen atom, a (C1-C6)alkyl group, or a (C1-C6)alkyloxy group,
R2 is a (C1-C6)alkyl, a phenyl or a heterocyclic group,

L represents a NH-CO-CH2 group,

R4 is a hydrogen, or a (C1-C6)alkyl group or a halogen in ortho of the L group,

the cycle 

is in meta or para position of the L group,

X1 and X2 are a nitrogen atom

R3 represents a hydrogen atom, a carbonyl(C1-C6)alkyl group, a SO2R' group, or a COOR' group.

9. The compound according to any one of the previous claims, characterized in that it is selected from:

2-[4-(4-acetylpiperazin-1-yl)phenyl]-N-{phenyl[2-(piperidin-1-yl)phenyl]methyl}acetamide;

2-[4-(4-acetylpiperazin-1-yl)phenyl]-N-{3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl}acetamide;

2-[5-(4-acetylpiperazin-1-yl)-2-methylphenyl]-N-{[4-methyl-2-(pyrrolidin-1-yl)phenyl](phenyl)methyl}acetamide;

tert-butyl 4-{4-fluoro-3-[({[4-methyl-2-(piperidin-1-yl)phenyl](phenyl)methyl}carbamoyl)methyl]phenyl}piperazine-1-carboxylate;

tert-butyl 4-{4-methyl-3-[({[4-methyl-2-(piperidin-1-yl)phenyl](phenyl)methyl}carbamoyl)methyl]phenyl}piperazine-1-carboxylate;

N-{[4-methyl-2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-[2-methyl-5-(piperazin-1-yl)phenyl]acetamide;

2-[2-fluoro-5-(piperazin-1-yl)phenyl]-N-{[4-methyl-2-(piperidin-1-yl)phenyl](phenyl)methyl}acetamide;

tert-butyl 4-{4-methyl-3-[({[4-methyl-2-(piperidin-1-yl)phenyl](5-methylfuran-2-yl)methyl}carbamoyl)methyl]phenyl}piperazine-1-carboxylate;

N-{[4-methyl-2-(piperidin-1-yl)phenyl](5-methylfuran-2-yl)methyl}-2-[2-methyl-5-(piperazin-1-yl)phenyl]acetamide;

2-[5-(4-acetylpiperazin-1-yl)-2-methylphenyl]-N-{[4-methyl-2-(piperidin-1-yl)phenyl](5-methylfuran-2-yl)methyl}acetamide;

2-[5-(4-acetylpiperazin-1-yl)-2-methylphenyl]-N-{[2-(azepan-1-yl)-4-methoxyphenyl](5-methylfuran-2-yl)methyl}acetamide;

2-[5-(4-acetylpiperazin-1-yl)-2-fluorophenyl]-N-[(2,4-dimethylphenyl)(5-methylfuran-2-yl)methyl]acetamide;

2-[5-(4-acetylpiperazin-1-yl)-2-fluorophenyl]-N-{[4-methyl-2-(piperidin-1-yl)phenyl](phenyl)methyl}acetamide;
2-[5-(4-acetylpiperazin-1-yl)-2-fluorophenyl]-N-{[2-(azepan-1-yl)-4-methoxyphenyl](5-methylfuran-2-yl)methyl}acetamide;
2-[5-(4-acetylpiperazin-1-yl)-2-methylphenyl]-N-{[2-(azepan-1-yl)-4-methoxyphenyl](phenyl)methyl}acetamide;
2-[2-fluoro-5-(4-methanesulfonylpiperazin-1-yl)phenyl]-N-{[4-methyl-2-(piperidin-1-yl)phenyl](5-methylfuran-2-yl)methyl}acetamide;
2-[5-(4-acetylpiperazin-1-yl)-2-fluorophenyl]-N-{[2-(azepan-1-yl)-4-methoxyphenyl](phenyl)methyl}acetamide;
2-[4-(4-methanesulfonylpiperidin-1-yl)phenyl]-N-{[4-methyl-2-(piperidin-1-yl)phenyl](5-methylfuran-2-yl)methyl}acetamide;
2-[4-(4-acetylpiperidin-1-yl)phenyl]-N-{[4-methyl-2-(piperidin-1-yl)phenyl](5-methylfuran-2-yl)methyl}acetamide;
2-[3-(4-acetylpiperazin-1-yl)phenyl]-N-{[4-methyl-2-(piperidin-1-yl)phenyl](5-methylfuran-2-yl)methyl}acetamide;
2-[2-fluoro-5-(4-methanesulfonylpiperidin-1-yl)phenyl]-N-{[4-methyl-2-(piperidin-1-yl)phenyl](5-methylfuran-2-yl)methyl}acetamide;
2-[3-(4-methanesulfonylpiperidin-1-yl)phenyl]-N-{[4-methyl-2-(piperidin-1-yl)phenyl](5-methylfuran-2-yl)methyl}acetamide;
N-{[4-methyl-2-(piperidin-1-yl)phenyl](5-methylfuran-2-yl)methyl}-2-[3-(4-methylpiperazin-1-yl)phenyl]acetamide;
N-{[4-methyl-2-(piperidin-1-yl)phenyl](5-methylfuran-2-yl)methyl}-2-[3-(4-sulfamoylpiperazin-1-yl)phenyl]acetamide; and
N-{[4-methyl-2-(piperidin-1-yl)phenyl](5-methylfuran-2-yl)methyl}-2-{3-[4-(trifluoroacetyl)piperazin-1-yl]phenyl}acetamide.

10. A combination product comprising:
i) a compound of formula (Ia) as defined in any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof; and
ii) another therapeutically active agent, such as a PPAR activator.

11. The combination product according to claim 10, component ii) is Elafibranor or seladelpar, saroglitazar, lanifibranor, pioglitazone or a pharmaceutically acceptable salt thereof.

12. The combination product according to claim 10 or 11, wherein the combination product is a composition comprising components i) and ii) and a pharmaceutically acceptable carrier.

13. The combination product according to claim 10 or 11, wherein the combination product is a kit of parts comprising components i) and ii), for sequential, separate or simultaneous use.

14. The combination product according to any one of claims 10 to 13, wherein components i) and ii) are formulated in an injectable suspension, a gel, an oil, a pill, a tablet, a suppository, a powder, a capsule, an aerosol, an oinment, a cream, a patch, or means of galenic forms for a prolonged and/or slow release.

15. The compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, for use as a medicament.

16. The compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, or the combination product according to any one of claims 10 to 13, for use in a method for the treatment of an autoimmune disease, an autoimmune-related disease, an inflammatory disease, a metabolic disease, a fibrotic disease, and a cholestatic disease.

17. Use of a compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating an autoimmune disease, an autoimmune-related disease, an inflammatory disease, a metabolic disease, a fibrotic disease, or a cholestatic disease.

18. Use of a compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, and another therapeutically active agent, such as a PPAR activator, in the preparation of a combination product for treating an autoimmune disease, an autoimmune-related disease, an inflammatory disease, a metabolic disease, a fibrotic disease, or a cholestatic disease.